Real‐world evidence for amyloid‐targeted therapies: Lecanemab and donanemab
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · 2026-07 · 18 (3)
DOI: 10.1002/dad2.70404 ↗Abstract
Abstract INTRODUCTION Real‐world safety data on amyloid‐targeted therapies in early Alzheimer's disease remain limited, particularly for modified donanemab titration and direct lecanemab–donanemab comparisons. METHODS Retrospective review of 172 amyloid‐positive patients treated with lecanemab ( n = 89) or donanemab (original titration n = 21; modified n = 62). The cohort included patients with ≥2 chronic comorbidities (72.7%), systemic autoimmune or hematologic disorders, and concurrent immunomodulators. RESULTS Amyloid‐related imaging abnormalities (ARIA) occurred in 11.2% (10/89) with lecanemab and 13.3% (11/83) with donanemab—less than in pivotal trials. Modified donanemab titration reduced ARIA versus the original protocol (8.1% vs 28.6%; p = 0.03) and TRAILBLAZER‐ALZ 6 (23.6%). No anaphylaxis occurred. Surveillance magnetic resonance imaging captured 95.2% of ARIA events. Within‐center comparison showed comparable safety between lecanemab and modified‐titration donanemab (all p ’s > 0.40). IRRs occurred in 12.0% (donanemab) and 9.0% (lecanemab). DISCUSSION In a real‐world cohort representing patients excluded from trials, ARIA and IRR rates matched or improved upon pivotal trials, supporting safe ATT use under FDA‐approved MRI intervals.
EUVIMED